Статья

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

David PiccioniDepartment of Neurosciences,University of California San Diego Moores Cancer Center, San Diego, CA, USAAchal S. AchrolDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USALesli A. KiedrowskiDepartment of Medical Affairs, Guardant Health, Redwood City, CA, USAKimberly C. BanksDepartment of Medical Affairs, Guardant Health, Redwood City, CA, USANajee BoucherDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USAGarni BarkhoudarianDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USADaniel F. KellyDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USATiffany JuarezDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USARichard B. LanmanDepartment of Medical Affairs, Guardant Health, Redwood City, CA, USAVictoria M. RaymondDepartment of Medical Affairs, Guardant Health, Redwood City, CA, USAMinhdan NguyenDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USAJudy TruongDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USAAnnie HengDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USAJaya M. GillDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USAMarlon Garzo SariaDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USASandeep C. PingleDepartment of Neurosciences,University of California San Diego Moores Cancer Center, San Diego, CA, USASantosh KesariDepartment of Translational Neurosciences and Neurotherapeutics,Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, USA

2019en

ABI

Аннотация

Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.

Перевод пока недоступен

Идентификаторы

DOI: 10.2217/cns-2018-0015

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar